The Top FCA Decisions of 2015 for Government Contractors
Client Alert | less than 1 min read | 02.16.16
From the Supreme Court’s decision rejecting the applicability of the Wartime Suspension of Limitations Act to several rulings widening the circuit split on the implied certification theory of liability, 2015 saw a number of important False Claims Act case law developments. In a "Feature Comment" published in The Government Contractor, C&M attorneys highlight the top ten decisions from 2015 on key issues—such as damages calculations, original source requirements, statistical sampling, and more—that will shape this ever-active area of litigation in 2016 and beyond.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
